Table 5.
Hematological Adverse Effects.
| Adverse effects | Cohorts | Comparisons between cohorts, P value | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACT | PCB | |||||||||||||
| Treatment | Paclitaxel + carboplatin | Paclitaxel + carboplatin + bevacizumab | ||||||||||||
| Women enrolled | 161 | 127 | ||||||||||||
| Grade | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | ≥1 | ≥2 | ≥3 | 4 |
| Thrombocytopenia | 36 (22) | 49 (30) | 35 (22) | 21 (13) | 20 (13) | 22 (17) | 35 (28) | 31 (24) | 25 (20) | 14 (11) | 0.305 | 0.193 | 0.355 | 0.854 |
| Neutropenia | 41 (26) | 37 (23) | 35 (22) | 28 (17) | 20 (12) | 30 (24) | 17 (13) | 17 (13) | 32 (25) | 31 (25) | 0.784 | 0.056 | 0.001 | 0.012 |
| Leukopenia | 9 (6) | 8 (5) | 68 (42) | 55 (34) | 21 (13) | 5 (4) | 4 (3) | 51 (40) | 38 (30) | 29 (23) | 0.591 | 0.479 | 0.406 | 0.041 |
| Anemia | 5 (3) | 65 (40) | 57 (35) | 20 (13) | 14 (9) | 1 (1) | 40 (31) | 43 (34) | 25 (20) | 18 (14) | 0.234 | 0.067 | 0.031 | 0.186 |
| Total hematological events | 91 | 159 | 126 | 124 | 75 | 58 | 96 | 142 | 120 | 92 | 0.042 | <0.0001 | 0.017 | 0.023 |
| Hematological event(s) per woman | 0.57 | 0.99 | 0.78 | 0.77 | 0.47 | 0.46 | 0.76 | 1.12 | 0.95 | 0.72 | ||||
Data presented as frequency.
The Fischer exact was performed for statistical analysis.
A p < 0.05 considered as significant.
Adverse effects defined as per CTCAE v5.0.